Recruiting
T-DXd
Phase 1 Lung Cancer
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Trial #: NCT04686305
Recruiting
T-DXd
Phase 2 Tumor-agnostic
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Trial #: NCT06271837
Recruiting
I-DXd
Phase 2 Lung Cancer
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Trial #: NCT06780098
Recruiting
HER3-DXd
Phase 1 Lung Cancer
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Trial #: NCT03260491
Recruiting
T-DXd
Phase 3 Gastric Cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Trial #: NCT06731478
Recruiting
R-DXd
Phase 2 Phase 3 Gynecologic Cancers
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Trial #: NCT06161025
Recruiting
T-DXd
Phase 1 Tumor-agnostic
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Trial #: NCT07015697
Recruiting
T-DXd
Phase 3 Gynecologic Cancers
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Trial #: NCT06819007
Recruiting
Pipeline Compounds
Phase 1 Phase 2 Tumor-agnostic
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Trial #: NCT05875168
Recruiting
Dato-DXd
Phase 3 Lung Cancer
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Trial #: NCT06350097
Pages: 1  2  3  4  5  6  7  

The content contained is taken is taken directly from public registry ClinicalTrials.gov and has not been edited.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.